Kyle Mikson
Stock Analyst at Canaccord Genuity
(0.48)
# 3,043
Out of 4,479 analysts
50
Total ratings
17.07%
Success rate
-31.67%
Average return
Main Sectors:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Buy | $30 → $38 | $28.26 | +34.47% | 4 | Jun 4, 2024 | |
| AKYA Akoya Biosciences | Maintains: Buy | $10 → $6 | $2.21 | +171.49% | 2 | May 14, 2024 | |
| NTRA Natera | Maintains: Buy | $100 → $130 | $107.81 | +20.58% | 2 | May 10, 2024 | |
| EXAS Exact Sciences | Maintains: Buy | $90 → $85 | $42.43 | +100.33% | 6 | May 9, 2024 | |
| TXG 10x Genomics | Maintains: Buy | $65 → $50 | $18.59 | +168.96% | 4 | Apr 29, 2024 | |
| TTOO T2 Biosystems | Maintains: Hold | $12 → $3 | $5.38 | -44.24% | 2 | Apr 29, 2024 | |
| QTRX Quanterix | Maintains: Buy | $32 → $25 | $12.68 | +97.16% | 4 | Apr 29, 2024 | |
| OLK Olink Holding AB (publ) | Reiterates: Hold | $26 | $25.55 | +1.76% | 2 | Mar 26, 2024 | |
| BDSX Biodesix | Reiterates: Buy | $3.5 | $1.53 | +128.76% | 2 | Mar 4, 2024 | |
| ILMN Illumina | Downgrades: Hold | $210 → $120 | $105.50 | +13.74% | 5 | Nov 10, 2023 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $17 → $15 | $1.20 | +1,150.00% | 5 | Oct 31, 2023 | |
| QSI Quantum-Si incorporated | Downgrades: Hold | $3.5 → $2 | $0.93 | +114.04% | 2 | Sep 25, 2023 | |
| VNRX VolitionRx | Maintains: Overweight | $3 → $2 | $0.62 | +223.10% | 2 | Aug 16, 2023 | |
| CSTL Castle Biosciences | Maintains: Buy | $60 → $40 | $21.19 | +88.77% | 2 | Jun 6, 2023 | |
| XGN Exagen | Maintains: Buy | $8 → $7 | $1.81 | +286.74% | 1 | Nov 15, 2022 | |
| LUCD Lucid Diagnostics | Maintains: Buy | $18 → $12 | $0.79 | +1,420.91% | 2 | Mar 29, 2022 | |
| PAVM PAVmed | Initiates: Overweight | $49 | $0.76 | +6,339.79% | 1 | Mar 30, 2021 | |
| ICAD iCAD, Inc. | Initiates: Overweight | n/a | $1.27 | - | 1 | Jan 29, 2021 | |
| AWH Aspira Women's Health | Initiates: Overweight | n/a | $0.99 | - | 1 | Jan 29, 2021 |
Guardant Health
Jun 4, 2024
Maintains: Buy
Price Target: $30 → $38
Current: $28.26
Upside: +34.47%
Akoya Biosciences
May 14, 2024
Maintains: Buy
Price Target: $10 → $6
Current: $2.21
Upside: +171.49%
Natera
May 10, 2024
Maintains: Buy
Price Target: $100 → $130
Current: $107.81
Upside: +20.58%
Exact Sciences
May 9, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $42.43
Upside: +100.33%
10x Genomics
Apr 29, 2024
Maintains: Buy
Price Target: $65 → $50
Current: $18.59
Upside: +168.96%
T2 Biosystems
Apr 29, 2024
Maintains: Hold
Price Target: $12 → $3
Current: $5.38
Upside: -44.24%
Quanterix
Apr 29, 2024
Maintains: Buy
Price Target: $32 → $25
Current: $12.68
Upside: +97.16%
Olink Holding AB (publ)
Mar 26, 2024
Reiterates: Hold
Price Target: $26
Current: $25.55
Upside: +1.76%
Biodesix
Mar 4, 2024
Reiterates: Buy
Price Target: $3.5
Current: $1.53
Upside: +128.76%
Illumina
Nov 10, 2023
Downgrades: Hold
Price Target: $210 → $120
Current: $105.50
Upside: +13.74%
Pacific Biosciences of California
Oct 31, 2023
Maintains: Buy
Price Target: $17 → $15
Current: $1.20
Upside: +1,150.00%
Quantum-Si incorporated
Sep 25, 2023
Downgrades: Hold
Price Target: $3.5 → $2
Current: $0.93
Upside: +114.04%
VolitionRx
Aug 16, 2023
Maintains: Overweight
Price Target: $3 → $2
Current: $0.62
Upside: +223.10%
Castle Biosciences
Jun 6, 2023
Maintains: Buy
Price Target: $60 → $40
Current: $21.19
Upside: +88.77%
Exagen
Nov 15, 2022
Maintains: Buy
Price Target: $8 → $7
Current: $1.81
Upside: +286.74%
Lucid Diagnostics
Mar 29, 2022
Maintains: Buy
Price Target: $18 → $12
Current: $0.79
Upside: +1,420.91%
PAVmed
Mar 30, 2021
Initiates: Overweight
Price Target: $49
Current: $0.76
Upside: +6,339.79%
iCAD, Inc.
Jan 29, 2021
Initiates: Overweight
Price Target: n/a
Current: $1.27
Upside: -
Aspira Women's Health
Jan 29, 2021
Initiates: Overweight
Price Target: n/a
Current: $0.99
Upside: -